Gynositol® Utilizes Myo-Inositol to Restore Women's Health
Gynov's Innovative Supplement Helps the Body Receive Sufficient Quantities of Myo-Inositol to Restore Ovarian Cellular Health
FORT LAUDERDALE, Fla., Dec. 17, 2021 /PRNewswire/ -- Women's health is an often neglected corner of the medical world. Conditions such as PolyCystic Ovary Syndrome (PCOS) and Endometriosis are often plagued with limited information and uninformed diagnoses. Gynov is an innovative French health company that is working to address this ongoing issue.
Gynov utilizes a combination of holistic medicine and stringent scientific research to address women's health. While fertility and pregnancy are focal points, chronic conditions and other challenges presented by the reproductive system are also taken into account. According to company founder, Pierre-Yves Mousset, MD, "Gynov commits to developing solutions that are based on scientific rigor, promoted by physicians, and take into consideration women's individual needs." Dr. Mousset also explains that his company's products are "dedicated to women's health to help them cope with their chronic conditions, along with their medical treatment."
Gynov's flagship product, Gynositol®, is an excellent example of these standards in action. Gynositol® is designed to address the metabolic cause of the condition, taking a holistic view of health and including multi-targeted concepts. That is to say, the products consider the health of the entire reproductive system, offering nutritional supplemental support through scientifically targeted ingredients.
One of the most important of these is Myo-inositol. Myo-inositol and its derivatives are essential for the proper functioning of cellular metabolism, especially when cells face important needs (folliculogenesis) PCOS is associated with a 5 fold higher urinary elimination of inositol leading to myo-inositol deficiency. Because inositols are essential to drive insulin through cells, a deficiency of this ingredient not only prevents folliculogenesis, but also generates an insulin-resistance which can lead to type II diabetes. To summarize, myo-inositol is just key to manage PCOS and therefore to conceive.
A primary way that Gynositol® targets women's reproductive health is by helping the body both with the uptake and processing of Myo-inositol. This plays a key role in restoring ovarian function and improving oocyte quality. It can also reduce insulin resistance and, by extension, help manage diabetes.
From addressing chronic conditions to increasing fertility, Gynositol® has already proven to be an effective tool for women's health. Myo-inositol has a powerful impact on the reproductive system. Its avoidance of invasive procedures is also noteworthy, as it offers women a way to bolster their reproductive health with minimal risk and maximum results.
About Gynov: Gynov was founded in Paris, France in 2016 by Pierre-Yves Mousset, MD. Gynov prides itself on using advanced scientific methods to develop high-quality, effective dietary supplements dedicated to women's health and beyond. These are created to support the efficacy of prescription drugs and help provide genuine solutions for female health concerns. For more information, please visit: https://gynov.com/.
Please direct inquiries to:
Kelley Lake
(954) 673-5443
[email protected]
SOURCE Gynov
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article